NAN Chart, page-184

ScoPo’s (actually Wilkie’s) Powerplays: Health stocks flat as ACCC scrutinises Sigma and Chemist Warehouse mergerHealth & Biotech
3 hours ago | Nadine McGrath

Study shows Nanosonics CORIS tech outperforms
Disinfection device maker Nanosonics (ASX:NAN) has announced a new study demonstrating that its CORIS technology outperforms manual cleaning in biofilm removal in endoscopes. The study has been accepted for publication in the Journal of Hospital Infection.

NAN says despite current cleaning and disinfection efforts, flexible endoscopes can remain long-term reservoirs for infectious organisms.

World leading expert on biofilm in endoscopes and co-author of the publication Dr Michelle Alfa says the results showing biofilm removal by the CORIS device are significant given challenges with biofilm in endoscope reprocessing.

“In particular, the device removed cyclic build up biofilm from the small diameter channels, while the current manual cleaning approach was not effective,” she says in an ASX announcement.

“New technologies are required to address this significant problem and CORIS represents an opportunity to improve endoscope reprocessing and help prevent endoscope associated infections.”

Wilkie says publications like this are key for adoption of new technologies.

“Hospital budgets are tight at the moment though, so we’re looking to see these pressures ease – hopefully before the new product launch,” he says.

Morgans has an add rating and 12-month target price of $3.50 for NAN.